Amgen panitumumab gets fast-track status
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen's epidermal growth factor receptor inhibitor panitumumab gets fast-track designation for treatment of metastatic colorectal cancer patients who have failed standard chemotherapy, the company announces Aug. 1. Amgen plans to initiate the BLA "by the end of 2005"; "the completed submission of the BLA could extend into the first quarter of 2006, depending on timing and outcome of clinical data." Prior to the fast-track designation, Amgen indicated it would submit panitumumab in the second half of 2005 (1Pharmaceutical Approvals Monthly April 2005, In Brief)...
You may also be interested in...
Amgen/Abgenix’ Panitumumab Slows Colorectal Cancer Progression By 46%
Amgen's pivotal Phase III study of panitumumab for third-line metastatic colorectal cancer treatment showed a highly statistically significant 46% decrease in tumor progression rate compared to best supportive care (p<0.000000001)
Amgen preps panitumumab NDA
Amgen plans to submit its epidermal growth factor receptor inhibitor panitumumab in the second half of 2005 for treatment of third-line colorectal cancer, the firm says March 29. Two Phase III trials, one each in the U.S. and EU, are ongoing. "In recent discussions with the FDA, we have obtained favorable opinion regarding the acceptability of these studies for U.S. registration," Senior Director-Licensing Anthony Gringeri, PhD, tells investors at the Smith Barney Citigroup Healthcare conference. Amgen maintains the monoclonal antibody has advantages over Bristol-Myers Squibb/ImClone's EGFR agent Erbitux (cetuximab), including "fewer infusion reactions"...
EU: Good News For IVDs And For Future Transparency Of Medtech Compliance
The IVD industry has long been awaiting a further extension of the deadlines for compliance with the IVD Regulation and for the launch date of the Eudamed database to be brought forward.